Evidence map›Paper›PMID 27279236›Full record

ReviewCritical reviews in oncogenesis2015

Estrogen Receptor-β and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer.

Nalo Hamilton, Diana Marquez-Garban, Vei H Mah, Yahya Elshimali, David Elashoff, Edward B Garon, Jaydutt Vadgama, Richard Pietras

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Critical reviews in oncogenesis, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Estrogen Receptor-β Gene Cytosine-Adenine (International journal of molecular sciences · 2023
    Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Nalo HamiltonUCLA School of Nursing, Los Angeles, CA; UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA.
Diana Marquez-GarbanUCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA; Department of Medicine, Division of Hematology-Oncology, UCLA David Geffen School of Medicine, Los Angeles, CA.
Vei H MahDepartment of Human Genetics, University of California at Los Angeles, Los Angeles, CA 90095; Department of Medicine, Division of Hematology-Oncology, UCLA David Geffen School of Medicine, Los Angeles, CA.
Yahya ElshimaliDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
David ElashoffUCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA; Department of Medicine, Division of General Internal Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA.
Edward B GaronDepartment of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Jaydutt VadgamaUCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA; Department of Medicine, Division of Cancer Research and Training, Charles Drew University School of Medicine and Science, Los Angeles, CA.
Richard PietrasUCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA; Department of Medicine, Division of Hematology-Oncology, UCLA David Geffen School of Medicine, Los Angeles, CA.
University of California, Los Angeles · USCharles R. Drew University of Medicine and Science · USUCLA Health · USUCLA Jonsson Comprehensive Cancer Center

Funding

UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
The Early Detection Research Network Biomarker Resource Laboratory at UCLAU24CA086366 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHIA, DAVID S. · 2000 to 2014
$7.3M
NCATS NIH HHS UL1 TR000124NCI NIH HHS U24 CA086366
6 · The paper itself

Abstract

Triple-negative breast cancers (TNBCs) lack estrogen receptor-α (ERα), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) amplification and account for almost half of all breast cancer deaths. This breast cancer subtype largely affects women who are premenopausal, African-American, or have BRCA1/2 mutations. Women with TNBC are plagued with higher rates of distant metastasis that significantly diminish their overall survival and quality of life. Due to their poor response to chemotherapy, patients with TNBC would significantly benefit from development of new targeted therapeutics. Research suggests that the insulin-like growth factor (IGF) family and estrogen receptor beta-1 (ERβ1), due to their roles in metabolism and cellular regulation, might be attractive targets to pursue for TNBC management. Here, we review the current state of the science addressing the roles of ERβ1 and the IGF family in TNBC. Further, the potential benefit of metformin treatment in patients with TNBC as well as areas of therapeutic potential in the IGF-ERβ1 pathway are highlighted.

Indexed as

Molecular Targeted TherapyAntineoplastic AgentsEstrogen Receptor betaFemaleHumansSomatomedinsTriple Negative Breast NeoplasmsAntineoplastic AgentsEstrogen Receptor betaSomatomedins

Identifiers

PMID27279236
PMCPMC5495464
OpenAlexW2305574656

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.